Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184882 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 1 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04184882 is a Phase 1 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 8 participants.
The verdict
NCT04184882, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of ASP0367. This study will also evaluate the pharmacokinetics, pharmacodynamics and efficacy on muscle function of ASP0367.
Interventions
- DRUG Placebo
- DRUG Bocidelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2022-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04184882
The ClinicalTrials.gov registry entry for NCT04184882 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04184882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04184882 about?
NCT04184882 is a clinical study titled "A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)". The primary purpose of this study is to evaluate the safety and tolerability of ASP0367. This study will also evaluate the pharmacokinetics, pharmacodynamics and efficacy on muscle function of ASP0367.
What is the current status of trial NCT04184882?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-02-24. Estimated completion is 2022-09-04.
What interventions are being tested in trial NCT04184882?
The interventions under investigation include: Placebo (DRUG), Bocidelpar (DRUG).
Who is sponsoring clinical trial NCT04184882?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.